ragistomig (ABL503)

Ex vivo assays utilizing patient-derived lung cancer organoids revealed that ABL503 (TJ-L14B) exhibits superior tumor-killing activity than that by benchmark PD-L1 antibody, Atezolizumab. Conclusions Our data indicate that PD-L1 and 4-1BB dual targeting bispecific antibody, ABL503 (TJ-L14B), shows potent 4-1BB agonistic activity and anti-tumor effect in a PD-L1-dependent fashion concomitant with 4-1BB+/CD8+ T cell activation and proliferation to overcome limitations of PD-(L)1-targeted therapy while minimizing the risk of peripheral toxicity. The phase 1 clinical trial in the U.S. is currently ongoing in patients with locally advanced or metastatic solid tumors (NCT04762641).